Electra Therapeutics CSO reports stock options
CSO Parry Graham reports option and preferred share holdings in Electra Therapeutics, including IPO-convertible Series A preferred stock.
Rhea-AI Filing Summary
Electra Therapeutics, Inc. (ETRA) reports that Chief Scientific Officer Parry Graham beneficially owns several employee stock options and Series A Convertible Preferred Stock. The options cover blocks of common stock at exercise prices of $4.40, $4.96, and $15.00 with expirations from 2033 to 2036, plus Series A Convertible Preferred Stock that will automatically convert into common stock upon the company’s initial public offering.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Parry Graham
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F3 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F5 | -- | -- | -- |
| holding | Series A Convertible Preferred Stock F6, F7 | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 527,003 contracts (Direct);
Series A Convertible Preferred Stock — 85,504 contracts (Direct)
Footnotes (7)
- F1. 1/4th of the total shares subject to this option vested one year after January 1, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F2. 1/48th of the total shares subject to this option shall vest monthly after January 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F3. 1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.
- F4. The shares subject to this option are fully vested upon the date of grant.
- F5. 1/4th of the total shares subject to this option shall vest monthly commencing on September 2, 2026.
- F6. Each share of Series A Convertible Preferred Stock (the "Preferred Stock") will automatically convert into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
- F7. 7,125 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/4th of the Restricted Shares shall vest monthly commencing from September 2, 2026.
Key Figures
Option exercise price: $4.40 per share
Underlying shares at $4.40: 101,147 shares
Option exercise price: $4.96 per share
+4 more
7 metrics
Option exercise price
$4.40 per share
Employee stock option over 101,147 underlying common shares expiring November 16, 2033
Underlying shares at $4.40
101,147 shares
Employee stock option early exercisable, subject to repurchase right
Option exercise price
$4.96 per share
Employee stock option over 219,562 underlying common shares expiring February 12, 2036
Underlying shares at $4.96
219,562 shares
Employee stock option, monthly vesting after January 1, 2026
Option exercise price
$15.00 per share
Employee stock options over several blocks including 155,979, 46,122 and 4,193 shares expiring September 16, 2036
Series A preferred underlying common
85,504 shares
Series A Convertible Preferred Stock automatically converts 1:1 into common upon IPO closing
Restricted Shares
7,125 shares
Common shares designated as Restricted Shares with vesting commencing September 2, 2026
Key Terms
Employee Stock Option (right to buy), Series A Convertible Preferred Stock, early exercisable, Issuer's right of repurchase, +1 more
5 terms
Employee Stock Option (right to buy) financial
"security titled "Employee Stock Option (right to buy)" with underlying common"
Series A Convertible Preferred Stock financial
"security titled "Series A Convertible Preferred Stock" convertible into common"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
early exercisable financial
"The shares subject to this option are early exercisable, subject to the Issuer's right"
Issuer's right of repurchase financial
"early exercisable, subject to the Issuer's right of repurchase"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider holdings did ETRA’s Chief Scientific Officer report on this Form 3?
Parry Graham reported employee stock options over multiple blocks of Electra Therapeutics common stock and Series A Convertible Preferred Stock that is convertible into 85,504 shares of common stock, reflecting his initial beneficial ownership position as an officer.
What are the key stock option terms reported by ETRA’s CSO?
Reported options include grants exercisable at $4.40 for 101,147 underlying shares expiring November 16, 2033, $4.96 for 219,562 shares expiring February 12, 2036, and $15.00 options over several blocks expiring September 16, 2036, all held directly.
How does ETRA’s Series A Convertible Preferred Stock held by the CSO convert?
Each share of Series A Convertible Preferred Stock automatically converts into 1 share of common stock upon the closing of Electra Therapeutics’ initial public offering, without further consideration. The reported holdings correspond to 85,504 underlying common shares and have no expiration date.
What are the vesting terms for the $4.40 stock option reported for ETRA?
For the $4.40 option over 101,147 shares, 1/4 of the total shares vested one year after January 1, 2024, and 1/48 vests on each monthly anniversary thereafter. The option is early exercisable, subject to Electra Therapeutics’ right of repurchase.
What vesting schedule applies to the $4.96 stock option reported by ETRA’s CSO?
For the $4.96 option over 219,562 shares, 1/48 of the total shares vests monthly after January 1, 2026. These shares are early exercisable, subject to Electra Therapeutics’ right of repurchase, according to the filed footnote.
Are any of the $15.00 stock options for ETRA fully vested?
Yes. One block of the $15.00 employee stock option, covering 46,122 underlying common shares and expiring September 16, 2036, is stated to be fully vested upon the date of grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
